Drug intelligence / Profile preview

OS-01 peptide

Development stage
Unknown
Lead developer
OneSkin
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Topical
01

Overview

OS-01 is a proprietary synthetic decapeptide (Decapeptide-52) developed by OneSkin and used as the active ingredient in their topical skin longevity products. It is scientifically characterized as a "senomorphic" or "senotherapeutic" peptide that targets cellular senescence—a key driver of skin aging—by reducing the burden of senescent cells and promoting healthier cell renewal. The mechanism involves modulating pathways associated with cellular aging to improve skin health at the molecular level. Clinical studies have shown that topical application of products containing the OS-01 peptide can reduce biological age markers in human skin models and improve visible signs of aging such as fine lines and loss of elasticity[3][6][7]. The peptide is formulated into various over-the-counter cosmetic creams marketed for daily use to support youthful skin appearance.

Brand names
OS-01 FACE Topical SupplementOS01 FACE Topical SupplementOS 01 FACE Topical SupplementOS-01 FACE SPF BS SPF 30 TINTED DEEPOS01 FACE SPF BS SPF 30 TINTED DEEPOS 01 FACE SPF BS SPF 30 TINTED DEEPOS-01 FACE SPF BS SPF30 UNTINTEDOS01 FACE SPF BS SPF30 UNTINTEDOS 01 FACE SPF BS SPF30 UNTINTED
Other names
OS-01 Senescence Blocking PeptideOS01 Senescence Blocking PeptideOS 01 Senescence Blocking PeptideOneSkin peptide
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on OS-01 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OS-01 peptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call